About this event
Join Cytonics CEO Joey Bose for a live investor webinar on March 18, where he’ll share an in‑depth update on how Cytonics is advancing CYT‑108, its next‑generation A2M‑based biologic designed to target osteoarthritis at its molecular root cause.
During this session, Joey will walk through key developments since the launch of Cytonics’ current Regulation Crowdfunding (Reg CF) campaign, progress toward upcoming clinical milestones, and how the team is positioning the company for its next phase of growth.
You’ll hear how capital raised to date is being deployed across clinical development and pipeline expansion, get an inside look at the path from Phase 1 data toward Phase 2, and see how Cytonics’ “Nature’s Blueprint, Perfected” approach fits into the broader osteoarthritis treatment landscape.
The webinar will conclude with a live Q&A, giving you the chance to ask questions directly and deepen your understanding of both the science behind CYT‑108 and the long‑term vision for Cytonics as a patient‑first, shareholder‑aligned biotech.
Hosted by
